Inclusion Criteria:  histologically confirmed esophageal squamous cell carcinoma patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria unresectable T2-4 N0-3 M0 confirmed by CT or MRI ECOG performance status 0-1 no previous chest radiotherapy, immunotherapy or biotherapy. hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60 ml/min bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline phosphatase ≤5 times UNL FEV1 >0.8 L CB6 within normal limits patients and their family signed the informed consents  Exclusion Criteria:  previous or recent another malignancy, except for nonmelanoma skin cancer or cervical cancer in situ contraindication for chemotherapy women in pregnancy, lactation period, or no pregnancy test 14 days before the first dose women who has the probability of pregnancy without contraception tendency of hemorrhage in other clinical trials within 30 days addicted in drugs or alcohol, AIDS patients uncontrollable seizure or psychotic patients without self-control ability severe allergy or idiosyncrasy not suitable for this study judged by researchers